{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:38Z","timestamp":1789726238357,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:33:29Z","timestamp":1725276809000},"page":"577-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current and Emerging Biologics for Atopic Dermatitis"],"prefix":"10.1016","volume":"44","author":[{"given":"Michael","family":"Nevid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaci.2014.12.1907","article-title":"Targeted therapy for allergic diseases: at the intersection of cutting-edge science and clinical practice","volume":"135","author":"Boguniewicz","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.08.001_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.iac.2020.06.004","article-title":"Biologics for atopic dermatitis","volume":"40","author":"Boguniewicz","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Research Support, N.I.H., Extramural Review","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI117408","article-title":"Differential in\u00a0situ cytokine gene expression in acute versus chronic atopic dermatitis","volume":"94","author":"Hamid","year":"1994","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0091-6749(96)70246-4","article-title":"In\u00a0vivo expression of IL-12 and IL-13 in atopic dermatitis","volume":"98","author":"Hamid","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.001_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.08.001_bib9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.iac.2024.08.001_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.08.001_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/pde.12867","article-title":"Study of the atopic march: development of atopic comorbidities","volume":"33","author":"Schneider","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jaci.2019.01.003","article-title":"Report from the National Institute of Allergy and Infectious Diseases workshop on \"Atopic dermatitis and the atopic march: Mechanisms and interventions\"","volume":"143","author":"Davidson","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.iac.2024.08.001_bib16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10086","key":"10.1016\/j.iac.2024.08.001_bib17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","article-title":"Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"80","author":"Blauvelt","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","article-title":"IL-4Ralpha blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis","volume":"140","author":"Callewaert","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","article-title":"Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial","volume":"21","author":"Paller","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.17791","article-title":"Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2024.08.001_bib24","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A\u00a0phase 2, open-label study of single-dose dupilumab in children aged 6\u00a0months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol : JEADV"},{"issue":"10356","key":"10.1016\/j.iac.2024.08.001_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6\u00a0months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pde.15518","article-title":"A\u00a0case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis","volume":"41","author":"Siegfried","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.iac.2024.08.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.05.014","article-title":"A\u00a0systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and Immunology","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.001_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.anai.2023.03.010","article-title":"Atopic dermatitis yardstick update","volume":"130","author":"Boguniewicz","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib31","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","article-title":"Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis","volume":"9","author":"Boguniewicz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","article-title":"Real-world persistence with dupilumab among adults with atopic dermatitis","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13555-023-01061-4","article-title":"Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year interim data from the PROSE registry","volume":"14","author":"Simpson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.iac.2024.08.001_bib34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.survophthal.2022.02.002","article-title":"Dupilumab-associated ocular manifestations: A review of clinical presentations and management","volume":"67","author":"Wu","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.001_bib35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40257-023-00804-5","article-title":"Dupilumab-associated arthritis: a dermatology-rheumatology perspective","volume":"24","author":"Woodbury","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2","volume":"429","author":"Popovic","year":"2017","journal-title":"J\u00a0Mol Biol"},{"issue":"11","key":"10.1016\/j.iac.2024.08.001_bib37","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.001_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","article-title":"Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"85","author":"Merola","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.iac.2024.08.001_bib43","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J\u00a0Mol Biol"},{"issue":"12","key":"10.1016\/j.iac.2024.08.001_bib44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2024.08.001_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40257-023-00793-5","article-title":"Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis","volume":"24","author":"Bernardo","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"22","key":"10.1016\/j.iac.2024.08.001_bib47","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1111\/bph.12823","article-title":"Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice","volume":"171","author":"Kasutani","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T\u00a0cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"issue":"21","key":"10.1016\/j.iac.2024.08.001_bib50","first-page":"2093","article-title":"Anti-interleukin-31 receptor a antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.08.001_bib52","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2024.08.001_bib54","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68\u00a0weeks: results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.iac.2024.08.001_bib55","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1172\/JCI34182","article-title":"OX40-OX40L interactions: a promising therapeutic target for allergic diseases?","volume":"117","author":"Wang","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.iac.2024.08.001_bib56","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.iac.2024.08.001_bib57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2011.05.016","article-title":"Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets","volume":"128","author":"Fujita","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J\u00a0Dermatol Sci"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib59","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10372","key":"10.1016\/j.iac.2024.08.001_bib60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iac.2024.08.001_bib61","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/cpt.2539","article-title":"OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005","volume":"111","author":"Saghari","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.iac.2024.08.001_bib62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.001_bib63","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.001_bib64","doi-asserted-by":"crossref","first-page":"2153578","DOI":"10.1080\/09546634.2022.2153578","article-title":"Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis","volume":"34","author":"Mastorino","year":"2023","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.iac.2024.08.001_bib65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"AAAAI\/ACAAI joint task force atopic dermatitis guideline panel. atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.001_bib66","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:39:41Z","timestamp":1728391181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000584"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.08.001","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Emerging Biologics for Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}